Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and Nanovibronix (NASDAQ:FEED – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Earnings & Valuation
This table compares Pulse Biosciences and Nanovibronix”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulse Biosciences | $350,000.00 | 10,658.43 | -$72.78 million | ($1.18) | -44.65 |
| Nanovibronix | $1.93 million | 0.26 | -$18.18 million | ($117.28) | -0.00 |
Analyst Recommendations
This is a breakdown of recent recommendations for Pulse Biosciences and Nanovibronix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulse Biosciences | 1 | 0 | 4 | 1 | 2.83 |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
Pulse Biosciences presently has a consensus target price of $45.25, indicating a potential downside of 14.12%. Given Pulse Biosciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Pulse Biosciences is more favorable than Nanovibronix.
Profitability
This table compares Pulse Biosciences and Nanovibronix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulse Biosciences | -6,755.78% | -94.42% | -79.96% |
| Nanovibronix | -1,093.61% | -60.73% | -48.48% |
Risk and Volatility
Pulse Biosciences has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.
Institutional and Insider Ownership
77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 12.2% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Pulse Biosciences beats Nanovibronix on 9 of the 15 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
